Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003773 · ClinicalTrials.gov registry record · Phase 1
IM-862 in Treating Patients With Recurrent Ovarian Cancer
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00003773 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 43 participants.
The verdict
NCT00003773, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with chemotherapy and surgery.
Interventions
- DRUG oglufanide disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1999-02 |
| Est. Completion | 2001-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003773
The ClinicalTrials.gov registry entry for NCT00003773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oglufanide disodium is the first listed.
NCT00003773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003773 about?
NCT00003773 is a clinical study titled "IM-862 in Treating Patients With Recurrent Ovarian Cancer". RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with chemotherapy and surgery.
What is the current status of trial NCT00003773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 1999-02. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00003773?
The interventions under investigation include: oglufanide disodium (DRUG).
Who is sponsoring clinical trial NCT00003773?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.